Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News 3M discontinues collaboration for HCAIs molecular tests

3M discontinues collaboration for HCAIs molecular tests

23rd June 2008

3M has announced that it has discontinued its collaboration agreement with Gen-Probe for the development of molecular tests for healthcare-associated infections (HCAIs).

The companies said the partnership has been discontinued as a result of technical incompatibilities between the proprietary microfluidics instruments platform from 3M and the nucleic acid molecular tests from Gen-Probe.

Under the original terms of the agreement Gen-Probe assumed responsibilities for assay development funded by 3M, while 3M paid milestones to Gen-Probe upon the attainment of specified technical and commercial landmarks.

3M paid the first of these milestones in the fourth quarter of last year.

The company restated its dedication to the development and delivery of products in this clinical area.

Chuck Kummeth, vice-president and general manager at 3M, said: “Our technology platforms are helping hospitals address the important issue of HCAIs.”

He added that the company would continue to provide its customers with solutions for the detection, prevention and control of infections.

In March 2007, 3M Health Care announced the launch of a new medical diagnostics business unit focused on the development and commercialisation of products to detect treatment-resistant microbes, such as methicillin-resistant Staphylococcus aureus.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.